Antaros Medical´s project TRISTAN, now approved by IMI

Paul Hockings

Paul Hockings

The Innovative Medicines initiative (IMI) has approved the 5-year project TRISTAN, led by Bayer and coordinated by the European Organisation for Research and Treatment of Cancer (EORTC). The Gothenburg-based company Antaros Medical is one of the project partners together with Chalmers University of Technology, EORTC, Bayer, Bioxydyn, GlaxoSmithKline and fifteen other actors. TRISTAN is a significant investment in imaging research in West Sweden. Other West Sweden collaborators in addition to Antaros include Chalmers, Västra Götalands Region, and Sahlgrenska Academy, who are all working to avoid toxicity in humans during drug development.

MedTech West adjunct professor Paul Hockings, also director if imaging at Antaros Medical says:

– We are very proud of being a partner in the TRISTAN consortium and that our MRI-models are used to find biomarkers to better predict toxicity in humans in drug development.
Read the complete article here>>





Antaros Medical is a strategic clinical imaging research and methodology company based in the BioVentureHub in Mölndal and in Uppsala, Sweden. Antaros Medical is pioneering new frontiers in innovative MRI and PET imaging methodologies to design and deliver clinical imaging studies for improved, evidence-based decision making in drug development. The company is specialized in cardio-metabolic diseases and oncology. Antaros Medical’s clients are spread across the globe.